{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:54:53Z","timestamp":1789584893125,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00535-026-02396-3","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T01:54:05Z","timestamp":1774230845000},"page":"1159-1169","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of peptide radionuclide therapy with 177Lu-DOTATATE in Japanese patients with advanced neuroendocrine neoplasm: a multicenter retrospective study (JON2203-N)"],"prefix":"10.1007","volume":"61","author":[{"given":"Kohei","family":"Okamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0394-6876","authenticated-orcid":false,"given":"Susumu","family":"Hijioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noritoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Imaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Horiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Shioji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Tsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Tobimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Asama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Arima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Unno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eizaburo","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Ashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Naganuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Murohisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironaga","family":"Satake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzo","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chigusa","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Japan Oncology Network in Hepatobiliary\u00a0and Pancreas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"2396_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335.","journal-title":"N Engl J Med"},{"key":"2396_CR2","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403:2807\u201317.","journal-title":"Lancet"},{"key":"2396_CR3","doi-asserted-by":"publisher","first-page":"334","DOI":"10.4143\/crt.2021.1022","volume":"55","author":"HG Ryoo","year":"2023","unstructured":"Ryoo HG, Suh M, Kang KW, et al. Phase 1 study of no-carrier added 177Lu-DOTATATE (SNU-KB-01) in patients with somatostatin receptor-positive neuroendocrine tumors: the first clinical trial of peptide receptor radionuclide therapy in Korea. Cancer Res Treat. 2023;55:334\u201343.","journal-title":"Cancer Res Treat"},{"key":"2396_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11523-023-01022-z","volume":"19","author":"Y Shin","year":"2024","unstructured":"Shin Y, Moon BH, Ryoo B-Y, et al. Efficacy and safety of Lu-177 DOTATATE peptide receptor radionuclide therapy in patients with unresectable or metastatic neuroendocrine tumors in Korea. Target Oncol. 2024;19:41\u20139.","journal-title":"Target Oncol"},{"key":"2396_CR5","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1007\/s12149-021-01674-9","volume":"35","author":"N Kobayashi","year":"2021","unstructured":"Kobayashi N, Takano S, Ito K, et al. Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA0-Tyr3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors. Ann Nucl Med. 2021;35:1332\u201341.","journal-title":"Ann Nucl Med"},{"key":"2396_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/jhbp.1101","volume":"29","author":"A Kudo","year":"2022","unstructured":"Kudo A, Tateishi U, Yoshimura R, et al. Safety and response after peptide receptor radionuclide therapy with 177 Lu-DOTATATE for neuroendocrine tumors in phase 1\/2 prospective Japanese trial. J Hepatobiliary Pancreat Sci. 2022;29:487\u201399.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2396_CR7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/jhbp.1014","volume":"28","author":"N Kobayashi","year":"2021","unstructured":"Kobayashi N, Wild D, Kaul F, et al. Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors. J Hepatobiliary Pancreat Sci. 2021;28:727\u201339.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2396_CR8","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335\u201342.","journal-title":"JAMA Oncol"},{"key":"2396_CR9","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1186\/s12885-020-07581-y","volume":"20","author":"T Masui","year":"2020","unstructured":"Masui T, Ito T, Komoto I, et al. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study. BMC Cancer. 2020;20:1104.","journal-title":"BMC Cancer"},{"key":"2396_CR10","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23:4617\u201324.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 2","key":"2396_CR11","first-page":"S219","volume":"31","author":"EP Krenning","year":"1999","unstructured":"Krenning EP, Valkema R, Kooij PP, et al. Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide. Ital J Gastroenterol Hepatol. 1999;31(Suppl 2):S219-223.","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"2396_CR12","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1007\/s00259-020-04709-x","volume":"47","author":"J Strosberg","year":"2020","unstructured":"Strosberg J, Kunz PL, Hendifar A, et al. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020;47:2372\u201382.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2396_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","volume":"76","author":"ID Nagtegaal","year":"2020","unstructured":"Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182\u20138.","journal-title":"Histopathology"},{"key":"2396_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13210","volume":"34","author":"S Alsadik","year":"2022","unstructured":"Alsadik S, Gnanasegaran G, Chen L, et al. Single centre retrospective review of outcome of 177 Lu-DOTATATE peptide receptor radionuclide therapy in the treatment of progressive metastatic neuroendocrine tumours: Survival, toxicity, and prognostic factors. J Neuroendocrinol. 2022;34:e13210.","journal-title":"J Neuroendocrinol"},{"key":"2396_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13138","volume":"34","author":"H Almeamar","year":"2022","unstructured":"Almeamar H, Cullen L, Murphy DJ, et al. Real-world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumours. J Neuroendocrinol. 2022;34:e13138.","journal-title":"J Neuroendocrinol"},{"key":"2396_CR16","doi-asserted-by":"publisher","first-page":"396","DOI":"10.37349\/etat.2023.00141","volume":"4","author":"S Hentzen","year":"2023","unstructured":"Hentzen S, Mehta K, Al-Rajabi RMT, et al. Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy. Explor Target Antitumor Ther. 2023;4:396\u2013405.","journal-title":"Explor Target Antitumor Ther"},{"key":"2396_CR17","doi-asserted-by":"publisher","first-page":"20201041","DOI":"10.1259\/bjr.20201041","volume":"94","author":"K Sitani","year":"2020","unstructured":"Sitani K, Parghane RV, Talole S, et al. Long-term outcome of indigenous 177Lu-DOTATATE PRRT in patients with Metastatic Advanced Neuroendocrine Tumours: a single institutional observation in a large tertiary care setting. Br J Radiol. 2020;94:20201041.","journal-title":"Br J Radiol"},{"key":"2396_CR18","doi-asserted-by":"publisher","first-page":"5617","DOI":"10.3390\/curroncol31090416","volume":"31","author":"L Piscopo","year":"2024","unstructured":"Piscopo L, Zampella E, Volpe F, et al. The safety and efficacy of peptide receptor radionuclide therapy for gastro-entero-pancreatic neuroendocrine tumors: a single center experience. Curr Oncol. 2024;31:5617\u201329.","journal-title":"Curr Oncol"},{"key":"2396_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2967\/jnumed.113.125336","volume":"55","author":"S Ezziddin","year":"2014","unstructured":"Ezziddin S, Attassi M, Yong-Hing CJ, et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2014;55:183\u201390.","journal-title":"J Nucl Med"},{"key":"2396_CR20","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1210\/jc.2018-01991","volume":"104","author":"WT Zandee","year":"2019","unstructured":"Zandee WT, Brabander T, Bla\u017eevi\u0107 A, et al. Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab. 2019;104:1336\u201344.","journal-title":"J Clin Endocrinol Metab"},{"key":"2396_CR21","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1016\/j.annonc.2024.05.219","volume":"35","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, et al. First-line efficacy of [177Lu]Lu-DOTA-TATE in patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors by tumor grade and primary origin: Subgroup analysis of the phase III NETTER-2 study. Ann Oncol. 2024;35:S92\u20133.","journal-title":"Ann Oncol"},{"key":"2396_CR22","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1001\/jamaoncol.2020.0078","volume":"6","author":"MB Sonbol","year":"2020","unstructured":"Sonbol MB, Halfdanarson TR, Hilal T. Assessment of therapy-related myeloid neoplasms in patients with neuroendocrine tumors after peptide receptor radionuclide therapy: a systematic review. JAMA Oncol. 2020;6:1086\u201392.","journal-title":"JAMA Oncol"},{"key":"2396_CR23","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1007\/s00259-020-05127-9","volume":"48","author":"M Chantadisai","year":"2021","unstructured":"Chantadisai M, Kulkarni HR, Baum RP. Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival. Eur J Nucl Med Mol Imaging. 2021;48:1390\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2396_CR24","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.3390\/jcm9072203","volume":"9","author":"MI Del Olmo-Garc\u00eda","year":"2020","unstructured":"Del Olmo-Garc\u00eda MI, Muros MA, L\u00f3pez-de-la-Torre M, et al. Prevention and management of hormonal crisis during theragnosis with LU-DOTA-TATE in neuroendocrine tumors. A systematic review and approach proposal. J Clin Med. 2020;9:2203.","journal-title":"J Clin Med."},{"key":"2396_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.03.002","volume":"66","author":"G Tapia Rico","year":"2018","unstructured":"Tapia Rico G, Li M, Pavlakis N, et al. Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): literature review and case series from two Australian tertiary medical institutions. Cancer Treat Rev. 2018;66:1\u20136.","journal-title":"Cancer Treat Rev"},{"key":"2396_CR26","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.1200\/JCO.2024.42.16_suppl.4131","volume":"42","author":"PL Kunz","year":"2024","unstructured":"Kunz PL, Ferone D, Halperin DM, et al. Safety and time to response of [177Lu]Lu-DOTATATE in patients with newly diagnosed advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Sub-analysis of the phase 3 randomized NETTER-2 study. JCO. 2024;42:4131\u20134131.","journal-title":"JCO"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02396-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-026-02396-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02396-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:07:32Z","timestamp":1785514052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-026-02396-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2396"],"URL":"https:\/\/doi.org\/10.1007\/s00535-026-02396-3","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kohei Okamoto has received honoraria from Novartis. Susumu Hijioka has received honoraria from Novartis and Teijin Healthcare. Noritoshi Kobayashi has received honoraria from Novartis, Teijin Healthcare, and Teijin Pharma. Hiroshi Imaoka has received research funding and honoraria from Novartis. Nao Fujimori has received honoraria from Novartis. Kentaro Sudo has received honoraria from Novartis. Takeshi Terashima has received honoraria from AstraZeneca, Chugai Pharmaceutical, and Eisai. Takaaki Furukawa has received honoraria from Novartis. Hidetaka Tsumura has received honoraria from Novartis. Hironaga Satake has received research funding from Asahi Kasei, Daiichi Sankyo, Kyo Diagnostics, MSD, Ono Pharmaceutical, Taiho Pharmaceutical, and Takeda Pharmaceutical; and honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, Merck Bio Pharma, MSD, Ono Pharmaceutical, Sanofi, Takeda Pharmaceutical, Taiho Pharmaceutical, and Yakult Honsha. Isao Yokota has received honoraria from Chugai Pharmaceutical and Pfizer. Hiroyuki Okuyama has received honoraria from AstraZeneca, Chugai Pharmaceutical, Novartis, and Taiho Pharmaceutical. Satoshi Shimizu has received research funding from AstraZeneca, Delta-Fly Pharma, Servier, and Taiho Pharmaceutical. Chigusa Morizane has received research funding from AstraZeneca, Boehringer Ingelheim, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Hitachi, Labcorp, Ono Pharmaceutical, Taiho Pharmaceutical, and Yakult Honsha; consulting fees from AbbVie, AstraZeneca, BioNTech SE, Boehringer Ingelheim, MSD, Pfizer, Revolution Medicines, and Servier; and honoraria from AstraZeneca, Chugai Pharmaceutical, Eisai, Guardant Health, MSD, Myriad Genetics, Novartis, Servier, and Taiho Pharmaceutical. Makoto Ueno has received research funding and honoraria from Novartis. Junji Furuse has received honoraria from Astellas Pharma, AstraZeneca, Chugai Pharmaceutical, Daiichi Sankyo, Delta-Fly Pharma, Eisai, Incyte, J-Pharma, MSD, Novartis, Ohara Pharmaceutical, Ono Pharmaceutical, OncoTherapy Science, Pfizer, Servier, Takeda, Taiho Pharmaceutical, Teijin, and TME Therapeutics. The other authors have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}